Literature DB >> 25855244

A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Thomas D Nolin1.   

Abstract

Unrecognized alterations in pharmacokinetics, which quantitatively describes the time course of drug disposition in the body, may lead to clinically significant changes in systemic exposure and corresponding response to drugs in patients with chronic kidney disease (CKD). Clinicians must take pharmacokinetic changes into consideration when selecting and dosing medications in CKD patients to optimize the risk:benefit ratio. Pharmacokinetic changes in absorption, distribution, and renal clearance are well characterized and generally predictable for most drugs. Conversely, changes in nonrenal clearance are less well understood and corresponding clinical implications are still being elucidated. This review provides a synopsis of alterations in each of these pharmacokinetic parameters observed in patients with advanced CKD.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 25855244      PMCID: PMC4496305          DOI: 10.1111/sdi.12374

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  60 in total

1.  Persistence of antibiotics in blood of patients with acute renal failure. I. Tetracycline and chlortetracycline.

Authors:  C M KUNIN; S B REES; J P MERRILL; M FINLAND
Journal:  J Clin Invest       Date:  1959-09       Impact factor: 14.808

2.  Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis.

Authors:  C M KUNIN; A J GLAZKO; M FINLAND
Journal:  J Clin Invest       Date:  1959-09       Impact factor: 14.808

Review 3.  Drug dosing in patients with impaired renal function.

Authors:  D C Brater
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

4.  The impact of continuous renal replacement therapy on drug therapy.

Authors:  G M Susla
Journal:  Clin Pharmacol Ther       Date:  2009-09-02       Impact factor: 6.875

5.  Pharmacokinetic studies in hemodialysis patients.

Authors:  A J Atkinson; J G Umans
Journal:  Clin Pharmacol Ther       Date:  2009-08-12       Impact factor: 6.875

6.  Nephropharmacology: drugs and the kidney.

Authors:  A J Atkinson; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2009-11       Impact factor: 6.875

Review 7.  Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.

Authors:  P N Maton; M E Burton
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

8.  The influence of chronic renal failure on drug metabolism and transport.

Authors:  A W Dreisbach
Journal:  Clin Pharmacol Ther       Date:  2009-09-23       Impact factor: 6.875

9.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Authors:  Thomas D Nolin; Reginald F Frye; Phuong Le; Hooman Sadr; Judith Naud; Francois A Leblond; Vincent Pichette; Jonathan Himmelfarb
Journal:  J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 10.121

10.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

View more
  11 in total

1.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

2.  Adverse Drug Effects in Patients with CKD: Primum Non Nocere.

Authors:  Mark A Perazella; Thomas D Nolin
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

3.  Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort.

Authors:  Solène M Laville; Marie Metzger; Bénédicte Stengel; Christian Jacquelinet; Christian Combe; Denis Fouque; Maurice Laville; Luc Frimat; Carole Ayav; Elodie Speyer; Bruce M Robinson; Ziad A Massy; Sophie Liabeuf
Journal:  Br J Clin Pharmacol       Date:  2018-09-24       Impact factor: 4.335

4.  Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling.

Authors:  Tacy Santana Machado; Stéphane Poitevin; Pascale Paul; Nathalie McKay; Noémie Jourde-Chiche; Tristan Legris; Annick Mouly-Bandini; Françoise Dignat-George; Philippe Brunet; Rosalinde Masereeuw; Stéphane Burtey; Claire Cerini
Journal:  J Am Soc Nephrol       Date:  2017-12-08       Impact factor: 10.121

Review 5.  Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease.

Authors:  Mena Raouf; Jeffrey Bettinger; Erica W Wegrzyn; Roy O Mathew; Jeffrey J Fudin
Journal:  Kidney Dis (Basel)       Date:  2020-01-20

6.  Adverse Drug Reactions in Patients with CKD.

Authors:  Solène M Laville; Valérie Gras-Champel; Julien Moragny; Marie Metzger; Christian Jacquelinet; Christian Combe; Denis Fouque; Maurice Laville; Luc Frimat; Bruce M Robinson; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-01       Impact factor: 8.237

7.  Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease.

Authors:  Roy O Mathew; Jeffrey J Bettinger; Erica L Wegrzyn; Jeffrey Fudin
Journal:  J Pain Res       Date:  2016-12-08       Impact factor: 3.133

Review 8.  Emerging Roles of Aryl Hydrocarbon Receptors in the Altered Clearance of Drugs during Chronic Kidney Disease.

Authors:  Tacy Santana Machado; Claire Cerini; Stéphane Burtey
Journal:  Toxins (Basel)       Date:  2019-04-07       Impact factor: 4.546

Review 9.  Pharmacokinetics in children with chronic kidney disease.

Authors:  Anne M Schijvens; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2019-08-02       Impact factor: 3.714

10.  A systematically collated library of prescribing safety indicators for people with chronic kidney disease.

Authors:  Fiona Smith; Samantha Hayward; Barnaby Hole; George Kimpton; Christine Sluman; Penny Whiting; Fergus Caskey
Journal:  BMC Nephrol       Date:  2020-11-18       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.